HomeCompareGILD vs BEN

GILD vs BEN: Dividend Comparison 2026

GILD yields 2.34% · BEN yields 5.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BEN wins by $36.0K in total portfolio value
10 years
GILD
GILD
● Live price
2.34%
Share price
$136.34
Annual div
$3.19
5Y div CAGR
17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,614.90
Full GILD calculator →
BEN
BEN
● Live price
5.63%
Share price
$22.91
Annual div
$1.29
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$65.2K
Annual income
$11,735.62
Full BEN calculator →

Portfolio growth — GILD vs BEN

📍 BEN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGILDBEN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GILD + BEN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GILD pays
BEN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GILD
Annual income on $10K today (after 15% tax)
$198.88/yr
After 10yr DRIP, annual income (after tax)
$1,372.67/yr
BEN
Annual income on $10K today (after 15% tax)
$478.61/yr
After 10yr DRIP, annual income (after tax)
$9,975.28/yr
At 15% tax rate, BEN beats the other by $8,602.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GILD + BEN for your $10,000?

GILD: 50%BEN: 50%
100% BEN50/50100% GILD
Portfolio after 10yr
$47.2K
Annual income
$6,675.26/yr
Blended yield
14.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GILD right now

GILD
Analyst Ratings
37
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$158.71
+16.4% upside vs current
Range: $105.00 — $180.00
Altman Z
4.1
Piotroski
8/9
BEN
Analyst Ratings
6
Buy
14
Hold
7
Sell
Consensus: Hold
Price Target
$23.50
+2.6% upside vs current
Range: $22.00 — $25.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GILD buys
0
BEN buys
0
No recent congressional trades found for GILD or BEN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGILDBEN
Forward yield2.34%5.63%
Annual dividend / share$3.19$1.29
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR17.3%22.6%
Portfolio after 10y$29.1K$65.2K
Annual income after 10y$1,614.90$11,735.62
Total dividends collected$7.6K$38.7K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyHold
Analyst price target$158.71$23.50

Year-by-year: GILD vs BEN ($10,000, DRIP)

YearGILD PortfolioGILD Income/yrBEN PortfolioBEN Income/yrGap
1← crossover$10,974$274.45$11,390$690.33$416.00BEN
2$12,073$330.19$13,089$900.94$1.0KBEN
3$13,316$398.20$15,191$1,186.21$1.9KBEN
4$14,730$481.49$17,832$1,577.47$3.1KBEN
5$16,345$583.87$21,202$2,121.67$4.9KBEN
6$18,199$710.26$25,576$2,890.42$7.4KBEN
7$20,340$866.96$31,362$3,995.15$11.0KBEN
8$22,826$1,062.22$39,170$5,613.10$16.3KBEN
9$25,731$1,306.80$49,945$8,032.75$24.2KBEN
10$29,147$1,614.90$65,177$11,735.62$36.0KBEN

GILD vs BEN: Complete Analysis 2026

GILDHealthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Full GILD Calculator →

BENStock

Franklin Resources, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to individuals, institutions, pension plans, trusts, and partnerships. It launches equity, fixed income, balanced, and multi-asset mutual funds through its subsidiaries. The firm invests in the public equity, fixed income, and alternative markets. Franklin Resources, Inc. was founded in 1947 and is based in San Mateo, California with an additional office in Hyderabad, India.

Full BEN Calculator →
📬

Get this GILD vs BEN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GILD vs SCHDGILD vs JEPIGILD vs OGILD vs KOGILD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.